| 133.75 -0.63 (-0.47%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 166.1 | 1-year : | 194 |
| Resists | First : | 142.21 | Second : | 166.1 |
| Pivot price | 136.36  |
|||
| Supports | First : | 129.32  |
Second : | 121.36 |
| MAs | MA(5) : | 134.64 |
MA(20) : | 136.1 |
| MA(100) : | 138.23 |
MA(250) : | 121.45 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 16.7 |
D(3) : | 21.4 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 161 | Low : | 85.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ASND ] has closed above bottom band by 14.1%. Bollinger Bands are 54.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 136.51 - 137.17 | 137.17 - 137.83 |
| Low: | 131.04 - 131.87 | 131.87 - 132.69 |
| Close: | 132.21 - 133.53 | 133.53 - 134.83 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Fri, 26 Jul 2024
Cantor Fitzgerald Brokers Raise Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND) - Defense World
Thu, 25 Jul 2024
Ascendis Pharma A/S Expected to Earn FY2024 Earnings of ($4.00) Per Share (NASDAQ:ASND) - MarketBeat
Tue, 23 Jul 2024
Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Seven Eight Capital LP - MarketBeat
Tue, 23 Jul 2024
SG Americas Securities LLC Makes New $288,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND) - Defense World
Sat, 20 Jul 2024
Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk - Simply Wall St
Tue, 16 Jul 2024
Quantbot Technologies LP Reduces Holdings in Ascendis Pharma A/S (NASDAQ:ASND) - American Banking and Market News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 5.69e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 3,420 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.5452e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -152.5 % |
| Return on Assets (ttm) | -51.3 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | 3.2902e+008 % |
| Gross Profit (p.s.) | 294.44 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -9.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -422 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 704.2 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.31 |
| Dividend | 0 |
| Forward Dividend | 3.54e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|